Bank of America’s Post

Thrilled to have attended the SCOPE conference alongside my Daiichi Sankyo, Inc. colleagues Starr Vang, Laura Naranjo, Kristine Koontz, PhD, MBA, Susie Campos, Mohammad F., Jehan Poco, and Kevin Douglass - a fantastic experience of collaboration and shared knowledge! Explored groundbreaking discussions on patient-centric trial design, highlighting the pivotal role of prioritizing the patient experience in shaping future trials. Discussed effective approaches to streamline site activation and start-up processes, fostering efficiency in the clinical trial journey. Delved into strategies for enhancing clinical trial diversity, emphasizing inclusivity for more robust and representative outcomes. Exciting times ahead in revolutionizing the future of clinical trials! #SCOPE2024 #ClinicalTrials #PatientCentricity #DiversityInResearch #Innovation

AI is a game changer for managing insights more timely, accurately, and effectively. Impatient Health and Within3 have a great panel assembled here for a valuable webinar. Join us!!!

A Global Approach to DEI in Clinical Trials Robina Weermeijer Boehringer Ingelheim As the world is becoming more and more diverse there is a big need to consider a wide audience when conducting clinical trials. In this presentation, you'll get insights into why it's important to look at diversity, equity, and inclusion on a global level and which efforts are being made by Boehringer Ingelheim in this space through collaboration with diverse stakeholders. https://bit.ly/3jRNCin #ScopeSummit #ClinicalTrials

Introducing Univo IRB’s new CEO, Julie Blasingim! Julie’s promotion to CEO starts a new chapter for the company as it continues to redefine IRB solutions and amplify patient voices. With 20+ years in clinical research, she brings invaluable expertise to drive both growth and innovation at Univo IRB. “Building on the momentum of Univo IRB’s recently announced new company name and plans to bring the voice of patients closer to research, Julie’s appointment as CEO continues the exciting new chapter for the organization.” - Michael Sorensen, partner at QHP Full article linked in the comments below. #lifesciences #mergersacquisitionsdivestitures #themanagementsystem

We will be at the DPHARM: Disruptive Innovations to Modernize Clinical Research conference with our partners Hawthornehealth and Acclinate. Meet our experts, Talley Mitchell and Alice Cheng, to learn how we are driving innovation and making clinical trials more accessible and effective. To discuss how we can collaborate, schedule a meeting with Talley: Or schedule a meeting with Alice: #ClinicalTrials #DPHARMA2024

New York's PE Healthcare Sector Weekly Round-up 🏥 📍Invidia Capital Management, founded by former Goldman Sachs Partner Jo Natauri, has officially launched with strategic investment from GCM Grosvenor. Based in New York, the firm will concentrate on middle-market healthcare investments across North America, targeting the long-term growth of healthcare assets. This launch marks a significant move in the healthcare investment sector, emphasizing a commitment to sustainable development and growth within the industry. 📍InTandem Capital Partners has announced an investment in Adams Clinical, a well-regarded clinical trial site network founded in 2011 in Watertown, MA. Adams Clinical operates multiple locations across the Northeast, conducting independent evaluations of drugs for physiological and neurological illnesses. This investment aims to support Adams Clinical's mission to redefine clinical trial execution, highlighting a continued effort to enhance and innovate within the clinical trials sector. 📍Royalty Pharma and Cytokinetics have teamed up in a strategic funding collaboration to boost the commercialization of aficamten, aiding the advancement of Cytokinetics' cardiovascular pipeline and enhancing capital access for its specialty cardiology business. The deal encompasses funding for commercialization plans, development, royalty restructuring, revenue sharing, and the acquisition of Cytokinetics equity. #rawselection #healthcare #privateequity #privateequitynews #healthcarenews #newyork #newyorknews

We’re excited to invite you to our upcoming webinar: Building Your Toolkit: How to Operationalize FDA Guidance on Diversity Join Stephanie Hitchcock, Director of Project Management – Start-Up at PCM Trials, and Kristofer Booth, MBA, Director of Strategic Partnerships at EmVenio Research, as they break down the latest FDA guidance on diversity in clinical research. Speakers will share actionable strategies to not only meet diversity goals but also improve participant optionality and boost overall trial success. In this webinar, attendees will: • Understand the key takeaways of the FDA’s latest guidance aimed at improving inclusivity in trials. • Explore how these guidelines empower underrepresented populations with more optionality and flexibility in clinical research. • Learn practical ways to integrate diversity into trial designs while maintaining overall study objectives. This webinar will take place on Thursday, November 14, 2024, at 10:00 am ET.   Register now: https://lnkd.in/gthAb-X9 #ClinicalResearch #DiversityInResearch #AccessForAll #Webinar #CommunityResearch #DiversityInTrials

Uncover the financial dynamics of the healthcare sector in the Benelux and France with Laura Roba and David Seynnaeve, our Sell-Side Equity specialists. What were the key takeaways from our healthcare seminar? We explore challenges in capital raising, dive into deal dynamics in oncology, neurology and obesity, and anticipate a surge in M&A activity throughout 2024. Stay updated on the innovative role of biotech companies and emerging opportunities in upcoming IPOs! #HealthcareSector #InvestmentInsights #Biotech #Markettrends2024 #IPO

Anticipating the future of the clinical trials industry in 2024 has sparked countless discussions 🌟 What truly excites me is witnessing tangible strides in innovation, particularly in patient-informed clinical trial design. Significant investments in software development are poised to redefine primary endpoints, offering biotech R&D the advantage of reduced sample sizes and a more comprehensive approach to addressing the holistic needs of patients undergoing treatment. 🤗 In a recent PharmaVoice feature on Crystal Ball predictions, Marc Buyse compellingly advocates for 2024 as the year of patient-driven trial design. Explore the insights from Marc and other industry thought leaders on the significant developments ahead: https://lnkd.in/egPc8e9j 💡 I invite you to delve into these perspectives and share your thoughts, predictions, or hopes for the future of clinical trials, increasingly shaped by patient preferences. Connect with me or drop your ideas in the comments! 🚀

This week, Bara Badwan is representing us on the West Coast at The Alliance for Artificial Intelligence in Healthcare (AAIH) and sharing our work on how our patented #AI solution identifies promising early-stage #biopharma assets and companies. You can read more about that here: https://lnkd.in/eTJReqfj. #pharmaceutical #portfoliostrategy